[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) are KIT-positive mesenchymal tumors of the gastrointestinal tract that are driven by activated KIT-signalling or platelet-derived growth factor receptor-alpha (PDFGRA) signaling.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • RESULTS: The leukemias developed 1.7 to 21 years after the GIST (median interval, 6 years).
  • None of the GIST patients had received radiotherapy or chemotherapy prior to the leukemia diagnosis.
  • All but 1 GIST case was found to have a low mitotic rate (0-1 per 50 high-power fields); however, tumor size varied from 3 to 18 cm (median, 4.5 cm).
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology


2. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • The Apc+/min mice have been widely used as a model recapitulating early intestinal adenoma formation.
  • To investigate whether tumor growth in Apc+/min mice is mediated by VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit VEGF-A: monotherapy with a monoclonal antibody (Mab) targeting VEGF-A and genetic deletion of VEGF-A selectively in intestinal epithelial cells.
  • Short-term (3 or 6 weeks) treatment with anti-VEGF-A Mab G6-31 resulted in a nearly complete suppression of adenoma growth throughout the small intestine.
  • Long-term (up to 52 weeks) treatment with Mab G6-31 led to a substantial increase in median survival.
  • Deletion of VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.
  • Therefore, VEGF-A inhibition may be a previously uncharacterized strategy for the prevention of the angiogenic switch and growth in intestinal adenomas.
  • [MeSH-minor] Adenoma / blood supply. Adenoma / genetics. Adenoma / immunology. Adenoma / therapy. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Gene Deletion. In Situ Hybridization. Intestinal Neoplasms / blood supply. Intestinal Neoplasms / genetics. Intestinal Neoplasms / immunology. Intestinal Neoplasms / therapy. Mice. Mice, Inbred C57BL. Signal Transduction / immunology. Survival Analysis. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


3. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • The patient was followed at our outpatient department for 19 months after operation and was free of the disease without any adjuvant chemotherapy.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Merchant NB, Parikh AA, Kooby DA: Should all distal pancreatectomies be performed laparoscopically? Adv Surg; 2009;43:283-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should all distal pancreatectomies be performed laparoscopically?
  • There are both enough experience and data (though retrospective) to confirm that LDP with or without spleen preservation appears to be a safe treatment for benign or noninvasive lesions of the pancreas.
  • Based on the fact that LDP can be performed with similar or shorter operative times, blood loss, complication rates, and length of hospital stay than ODP, it can be recommended as the treatment of choice for benign and noninvasive lesions in experienced hands when clinically indicated.
  • It is very difficult to make clear recommendations with regard to laparoscopic resection of malignant pancreatic tumors due to the lack of conclusive data.
  • Potential benefits of laparoscopic resection for cancer include the ability to inspect the abdomen and abort the procedure with minimal damage if occult metastases are identified.
  • This does not delay the onset of palliative chemotherapy, which would be the primary treatment in that circumstance.
  • In fact, there is evidence to suggest that there is a greater likelihood of receiving systemic therapy if a laparotomy is avoided in patients who have radiologically occult metastases.
  • Faster wound healing may also translate into a shorter waiting time before initiating adjuvant chemotherapy and/or radiation therapy.
  • Another aspect that draws some controversy is that of the totally laparoscopic procedure versus the hand-access approach.
  • The HALS approach allows for this, and the opportunity to control bleeding during the procedure.
  • Finally, it is important to remember that if the procedure is failing to progress laparoscopically, or if cancer surgery principles are likely to be violated, the surgeon (and the patient) must be willing to abort the laparoscopic approach and complete the operation using standard open technique.
  • Additional areas of discovery are in staple line reinforcement for left pancreatectomy and suturing technology for pancreatico-intestinal anastomosis.
  • Can we enucleate a small tumor off the pancreatic body by passing an endoscope through the gastric (or colonic) wall, and bring the specimen out via the mouth or anus?
  • Pioneers have already developed a porcine model of left pancreatectomy.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845186.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


5. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • Endocrine tumors (ET) of the digestive tract (formerly called neuroendocrine tumors) are rare.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • For gastrinoma with NEM-I, the benefit of surgical resection for tumors less than 2-3 cm in size is not clear.
  • The lesions are frequently small, multiple, and widespread and recurrence is frequent after excision.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


6. Knudsen AL, Bülow S: [Desmoid tumor in familial adenomatous polyposis]. Ugeskr Laeger; 2000 Oct 16;162(42):5628-31
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor in familial adenomatous polyposis].
  • [Transliterated title] Desmoid tumor ved familiaer adenomatøs polypose.
  • INTRODUCTION: Desmoid tumors (DT) are rare benign tumors that do not metastasize, but tend to invade locally.
  • DT are frequently seen in patients with familial adenomatous polyposis (FAP), and diagnosis and treatment are often difficult.
  • METHOD: The article presents the clinical picture, diagnosis and treatment of DT in patients registered in the Danish Polyposis Register by the end of 1999.
  • RESULTS: Twenty-seven of 486 patients (6%) had DT.
  • Eighteen patients were alive at the time of evaluation.
  • DT were found in the mesentery in 42%, in the abdominal wall in 40%, in the retroperitoneum in 8% and only 10% on the extremities.
  • Fifty percent of the patients had complications (intestinal obstruction, hydronephrosis or fistulas), and 2/9 deaths were caused by DT.
  • Ninety-three percent were treated with surgery, NSAIDs, antioestogenic drugs, chemotherapy or radiotherapy, but all modalities proved disappointing, except for treatment with a combination of the NSAID sulindac and tamoxifen.
  • DISCUSSION: Surgical excision is recommended in patients with DT in the abdominal wall.
  • First line treatment of mesenteric DT is Clinoril in combination with tamoxifen.
  • Elective surgery may be considered in patients with a small well-defined DT with no signs of invasion of vital structures, and in patients with imminent bowel ischaemia or obstruction.
  • The prognosis for mesenteric DT is grave, and improvement of the therapeutic strategy awaits current international studies.
  • [MeSH-major] Abdominal Neoplasms. Adenomatous Polyposis Coli. Fibromatosis, Aggressive. Peritoneal Neoplasms. Retroperitoneal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Colectomy. Colonic Neoplasms / complications. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Male. Prognosis. Registries

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059301.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • This tumor rarely develops in the gastrointestinal tract, with no more than 30 cases described in the literature.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • We performed exploratory laparotomy and found at least 15 solid whitish tumors attached to the wall of the small intestine, as well as to the parietal peritoneum.
  • All of the tumors were excised, most of which were about 10 cm in diameter.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Wu L, Zhang W, Li H, Li L, Kong W, Liu L: [Clinical analysis of 74 cases with ovarian thecoma]. Zhonghua Fu Chan Ke Za Zhi; 2002 Feb;37(2):101-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinical pathologic characteristics, treatment and prognostic factors of ovarian thecoma.
  • METHODS: From 1958 approximately 1998, a total of 74 patients with benign and malignant thecoma were retrospectively analyzed.
  • RESULTS: The reviewed diagnosis were 8 patients with malignant thecoma, 66 patients were benign thecoma.
  • Nine of 66 patients with benign thecoma appeared cell proliferative activity.
  • Fifteen patients with benign thecoma were evaluated blood serum CA(125), the CA(125) were elevated in 9 of 15 patients.
  • In 2 of 9 patients with cell proliferative activity, the tumors invaded adjacent tissues or relapsed, after received operation and pelvic radiotherapy, they are alive 11 years and 27 years respectively.
  • Among 8 patients with malignant thecoma, 4 patients without postoperation therapy or with non-standard chemotherapy died in 2 years postoperation, the other 4 patients received operation, postoperational radiotherapy or (and) chemotherapy, 1 of 4 patients died of irradiation intestinal fistule 4 years later; two patients are alive without disease more than 10 years, another one for 2 years.
  • CONCLUSIONS: Theca cell tumor of ovary have good prognosis, but we should pay attention to thecomas with proliferative activity.
  • The prognosis of malignant thecomas is poor, postoperative systemic chemotherapy or radiotherapy to the patients with malignant thecomas can improve their survival.
  • [MeSH-major] Ovarian Neoplasms / pathology. Thecoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11953075.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Casper ES: Gastrointestinal stromal tumors. Curr Treat Options Oncol; 2000 Aug;1(3):267-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors.
  • The nonepithelial, nonlymphoid tumors of the gastrointestinal tract are heterogeneous in terms of clinical presentation, behavior, pathology, and genetic features.
  • Concepts regarding these tumors have changed rapidly over the past decade as nomenclature has evolved.
  • Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms.
  • With an improved understanding of the biology of these tumors, gastrointestinal stromal tumor (GIST) is used as a specific term for tumors of the gastrointestinal tract that lack markers of myogenic differentiation, but stain positive for vimentin, and express CD34 and CD117, the product of the c-kit oncogene.
  • Both benign and malignant types are recognized.
  • In addition to myogenic tumors and GIST, gastrointestinal autonomic nerve tumors (GANT) are also recognized.
  • Complete en bloc surgical resection, when possible, is the cornerstone of therapy.
  • Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon.
  • Operation may palliate patients with intestinal obstruction or other symptoms.
  • For patients with unresectable disease, the results with systemic chemotherapy have been dismal.
  • Treatment with doxorubicin/ifosfamide combinations is of dubious value.
  • Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients.
  • The impact of such treatment on outcome, however, is poorly studied.
  • Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Humans. Radiotherapy. Stromal Cells / pathology. Survival Rate

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):926-32 [2067035.001]
  • [Cites] Ultrastruct Pathol. 1996 Jul-Aug;20(4):373-93 [8837346.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2083-8 [7697597.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):379-92 [9536485.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):413-9 [10448292.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):887-97 [8394653.001]
  • [Cites] Am J Surg Pathol. 1986;10 Suppl 1:83-99 [3296804.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1633-6 [9881963.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):287-90 [9891767.001]
  • [Cites] N Engl J Med. 1993 Apr 15;328(15):1107-14 [8455669.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] Gastrointest Endosc. 1997 Jun;45(6):468-73 [9199902.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] J Allergy Clin Immunol. 1997 Oct;100(4):435-40 [9338533.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • (PMID = 12057170.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


10. Priest JR, Williams GM, Hill DA, Dehner LP, Jaffé A: Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol; 2009 Jan;44(1):14-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Asymptomatic cysts present a therapeutic dilemma: surgical intervention and "conservative" observation have advocates.
  • This unique biology of PPB can inform the cyst management decision.
  • The earliest manifestation of PPB is a malignant lung cyst in young children, clinically and radiographically indistinguishable from benign congenital lung cysts.
  • Histopathologic examination differentiates cystic PPB from the benign cystic variants.
  • Surgical excision of cystic PPB (with or without chemotherapy) cures approximately 85-90% of children.
  • Detailed family history may reveal the hallmarks of PPB in the patient or young relatives: a unique constellation of diseases including lung cysts, cystic nephroma, childhood cancers, stromal sex-chord ovarian tumors, seminomas or dysgerminomas, intestinal polyps, thyroid hyperplasias, and hamartomas.
  • These diagnoses predict that a lung cyst is more likely PPB than a benign congenital cyst.
  • [MeSH-major] Cysts / pathology. Lung Diseases / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Pulmonol. 2010 Jan;45(1):103; author reply 104 [19960525.001]
  • (PMID = 19061226.001).
  • [ISSN] 1099-0496
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


11. Blanchard DK, Budde JM, Hatch GF 3rd, Wertheimer-Hatch L, Hatch KF, Davis GB, Foster RS Jr, Skandalakis JE: Tumors of the small intestine. World J Surg; 2000 Apr;24(4):421-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the small intestine.
  • This collective review includes all available case reports and series of smooth muscle (stromal) tumors of the small intestine in the world literature from 1881 to 1996.
  • The peak incidence of smooth muscle tumors in the small intestine in both male and female patients was between the ages of 50 and 59.
  • Computed tomography was found to detect LM and LMS most successfully and had the additional advantage of locating metastatic disease.
  • The jejunum contained the highest numbers of smooth muscle tumors, followed by the ileum and then the duodenum, with malignant lesions in all locations typically attaining larger diameters than benign tumors.
  • For both benign and malignant smooth muscle tumors of the small intestine, surgery remains the treatment of choice, with little efficacy reported for irradiation, chemotherapy, or both.
  • [MeSH-major] Intestinal Neoplasms / classification. Intestine, Small / pathology. Leiomyoma / classification. Leiomyosarcoma / classification
  • [MeSH-minor] Age Factors. Female. Gastrointestinal Hemorrhage / physiopathology. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Sex Factors. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10706914.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 60
  •  go-up   go-down


12. Galimberti A, Compagnoni BM, Lezziero F, Grassi M, Gariboldi M, Ferrante F: [Gastrointestinal stromal tumours and acute haemorrhage: description of four cases]. Chir Ital; 2005 May-Jun;57(3):337-43
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumori stromali del tratto gastroenterico ed emorragia acuta: descrizione di quattro casi.
  • Gastrointestinal stromal tumours are uncommon neoplasias arising from stromal tissue of the intestinal wall.
  • The clinical symptoms of gastrointestinal stromal tumours are related to tumour size and are generally aspecific: acute or chronic bleeding, abdominal pain and palpable mass are some of the most common signs.
  • Surgery is the only curative therapy for gastrointestinal stromal tumours.
  • Chemotherapy or radiotherapy are of no use for metastatic disease, but good results are obtained with ST1571 in advanced disease.
  • In the absence of metastases, it is quite difficult to distinguish between benign and malignant lesions.
  • The most important prognostic factors are number of mitoses and tumour size.
  • [MeSH-major] Duodenal Neoplasms / surgery. Gastrointestinal Hemorrhage / etiology. Gastrointestinal Hemorrhage / surgery. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Acute Disease. Aged. Endosonography. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231822.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Masferrer J: Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J; 2001 Nov-Dec;7 Suppl 3:S144-50
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 is inducible and is present in inflammatory foci, tumors, and neovasculature.
  • Expression of COX-2 appears to be important in tumor promotion, growth, and metastasis.
  • COX inhibitors have a major role in the treatment of inflammation and pain.
  • Epidemiologic evidence in patients who take nonsteroidal anti-inflammatory drugs links COX inhibition with decreases in malignant esophageal, stomach, colon, lung, and breast tumors.
  • Nonselective COX inhibitors have demonstrated efficacy in control of familial adenomatous polyposis, a disorder associated with the development of thousands of benign intestinal polyps.
  • Angiogenesis is a feature of both benign and malignant disease.
  • Because COX-2 is up-regulated in the neovasculature of the rheumatoid pannus and in malignant tumors and their surrounding stroma, selective COX-2 inhibitors may be able to modify the progression of these disorders through the control of angiogenesis.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Celecoxib. Colonic Neoplasms / drug therapy. Colonic Neoplasms / enzymology. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Humans. Isoenzymes / biosynthesis. Isoenzymes / drug effects. Membrane Proteins. Neovascularization, Pathologic / prevention & control. Prostaglandin-Endoperoxide Synthases / biosynthesis. Prostaglandin-Endoperoxide Synthases / drug effects. Prostaglandins / metabolism. Pyrazoles

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779086.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Prostaglandins; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 38
  •  go-up   go-down


14. Eyssartier E, Harper L, Michel JL, Rivière JP, Vanderbecken S, De Napoli-Cocci S: Rapidly growing mature retroperitoneal teratomas. J Pediatr Hematol Oncol; 2009 Sep;31(9):705-6
MedlinePlus Health Information. consumer health - Premature Babies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retroperitoneal mature teratomas are rare benign tumors, most commonly found in neonates and young adults.
  • In both cases, during the delay between diagnosis and surgery, the tumors practically doubled in size every 10 days.
  • We believe the possibility of rapid growth of these tumors implies that treatment should be conducted as soon as possible.
  • [MeSH-major] Infant, Premature, Diseases / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Abdominal Abscess / diagnosis. Cell Division. Diagnostic Errors. Disease Progression. Early Diagnosis. Enterocolitis, Necrotizing / complications. Enterocolitis, Necrotizing / drug therapy. Enterocolitis, Necrotizing / ultrasonography. Female. Humans. Incidental Findings. Infant. Infant, Newborn. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Malnutrition / complications. Nephrectomy. Remission Induction. Tomography, X-Ray Computed. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684525.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Mathieu N: [Risk of long-term treatment with proton pump inhibitors]. Rev Prat; 2008 Sep 15;58(13):1451-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk of long-term treatment with proton pump inhibitors].
  • [Transliterated title] Risques des traitements prolongés par les inhibiteurs de la pompe a protons.
  • Proton pump inhibitors (PPIs) have become the mainstay of therapy in acid-related upper gastrointestinal disorders including gastroesophageal reflux disease and peptic ulcer disease.
  • Alltough these medications are generally accepted as safe, the long-term clinical consequences of the inducing hypochlorhydria are not completely clear.
  • Gastric endocrine cell hyperplasia can occur in 10 to 30% of patients without carcinoid tumors.
  • Proton pump inhibitor-associated gastric polyps are totally benign tumors that should not be followed.
  • PPIs do not inhibit intestinal absorption of lipids, iron, phosphorus, magnesium or zinc from food but can affect vitamin B12 status in older patients.
  • [MeSH-minor] Bacterial Infections / chemically induced. Colonic Neoplasms / chemically induced. Gastric Acid / secretion. Gastrins / blood. Gastrins / drug effects. Humans. Polyps / chemically induced. Vitamin B 12 Deficiency / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18924330.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gastrins; 0 / Proton Pump Inhibitors
  •  go-up   go-down


16. Lipkin M: Early development of cancer chemoprevention clinical trials: studies of dietary calcium as a chemopreventive agent for human subjects. Eur J Cancer Prev; 2002 Aug;11 Suppl 2:S65-70
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early cancer chemoprevention clinical trials in human subjects had to be carried out with large numbers of subjects studied for long durations, measuring cancer as an end point.
  • However new findings on abnormal epithelial cell growth and development during the multistage evolution of colonic tumors made it possible to carry out chemoprevention clinical trials in several stages, with fewer subjects studied for shorter durations, thus enabling investigators to analyze increasing numbers of chemopreventive agents and nutritional regimens in clinical trials.
  • Early- and late-stage intermediate biomarker studies in humans have strongly suggested utility for supplemental dietary calcium to inhibit the development of benign and subsequent malignant colonic neoplasms.
  • Preclinical experimental studies have further demonstrated the ability of increased dietary calcium to inhibit the evolution of colonic tumors when they were induced by targeted mutations, dietary factors, and particularly when given over a long duration of lifespan.
  • [MeSH-major] Anticarcinogenic Agents / administration & dosage. Calcium, Dietary / administration & dosage. Chemoprevention / methods. Clinical Trials as Topic. Colonic Neoplasms / prevention & control. Intestinal Mucosa / drug effects. Precancerous Conditions / drug therapy

  • MedlinePlus Health Information. consumer health - Calcium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12570337.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Biomarkers; 0 / Calcium, Dietary
  • [Number-of-references] 44
  •  go-up   go-down






Advertisement